Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Archives of Virology
Published in: Archives of Virology 7/2018

01-07-2018 | Brief Report

Piperacillin and ceftazidime produce the strongest synergistic phage–antibiotic effect in Pseudomonas aeruginosa

Authors: Jumpei Uchiyama, Ryu Shigehisa, Tadahiro Nasukawa, Keijiro Mizukami, Iyo Takemura-Uchiyama, Takako Ujihara, Hironobu Murakami, Ichiro Imanishi, Koji Nishifuji, Masahiro Sakaguchi, Shigenobu Matsuzaki

Published in: Archives of Virology | Issue 7/2018

Login to get access

Abstract

The combined use of phage and antibiotics can show synergistic antimicrobial effects, so-called phage–antibiotic synergy (PAS). Here, we screened and examined PAS against Pseudomonas aeruginosa in vitro. Testing four different phages infecting P. aeruginosa, phage KPP22 classified within the family Myoviridae genus Pbunavirus showed PAS with the widest range of antibiotics, and showed PAS with anti-Pseudomonas drugs such as piperacillin and ceftazidime. Thus, evidence suggests that the combined use of phage and antibiotics is a promising therapeutic strategy against P. aeruginosa infections, with consideration needed regarding the optimal selection and adequate application timing of these phages and antibiotics.
Appendix
Available only for authorised users
Literature
1.
Matsuzaki S, Rashel M, Uchiyama J, Sakurai S, Ujihara T, Kuroda M, Ikeuchi M, Tani T, Fujieda M, Wakiguchi H, Imai S (2005) Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. J Infect Chemother 11:211–219CrossRefPubMed
2.
Pires DP, Vilas Boas D, Sillankorva S, Azeredo J (2015) Phage therapy: a step forward in the treatment of Pseudomonas aeruginosa infections. J Virol 89:7449–7456CrossRefPubMedPubMedCentral
3.
Krylov VN (2014) Bacteriophages of Pseudomonas aeruginosa: long-term prospects for use in phage therapy. Adv Virus Res 88:227–278CrossRefPubMed
4.
Aleshkin AV, Ershova ON, Volozhantsev NV, Svetoch EA, Popova AV, Rubalskii EO, Borzilov AI, Aleshkin VA, Afanas’ev SS, Karaulov AV, Galimzyanov KM, Rubalsky OV, Bochkareva SS (2016) Phagebiotics in treatment and prophylaxis of healthcare-associated infections. Bacteriophage 6:e1251379CrossRefPubMedPubMedCentral
5.
Sansom C (2015) Phage therapy for severe infections tested in the first multicentre trial. Lancet Infect Dis 15:1384–1385CrossRefPubMed
6.
Wright A, Hawkins CH, Anggard EE, Harper DR (2009) A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol 34:349–357CrossRefPubMed
7.
Bedi MS, Verma V, Chhibber S (2009) Amoxicillin and specific bacteriophage can be used together for eradication of biofilm of Klebsiella pneumoniae B5055. World J Microbiol Biotechnol 25:1145–1151CrossRef
8.
Kamal F, Dennis JJ (2015) Burkholderia cepacia complex Phage-Antibiotic Synergy (PAS): antibiotics stimulate lytic phage activity. Appl Environ Microbiol 81:1132–1138CrossRefPubMedPubMedCentral
9.
Chhibber S, Kaur T, Sandeep K (2013) Co-therapy using lytic bacteriophage and linezolid: effective treatment in eliminating methicillin resistant Staphylococcus aureus (MRSA) from diabetic foot infections. PLoS One 8:e56022CrossRefPubMedPubMedCentral
10.
Rahman M, Kim S, Kim SM, Seol SY, Kim J (2011) Characterization of induced Staphylococcus aureus bacteriophage SAP-26 and its anti-biofilm activity with rifampicin. Biofouling 27:1087–1093CrossRefPubMed
11.
12.
Comeau AM, Tetart F, Trojet SN, Prere MF, Krisch HM (2007) Phage-Antibiotic Synergy (PAS): beta-lactam and quinolone antibiotics stimulate virulent phage growth. PLoS One 2:e799CrossRefPubMedPubMedCentral
13.
Ryan EM, Alkawareek MY, Donnelly RF, Gilmore BF (2012) Synergistic phage-antibiotic combinations for the control of Escherichia coli biofilms in vitro. FEMS Immunol Med Microbiol 65:395–398CrossRefPubMed
14.
Knezevic P, Curcin S, Aleksic V, Petrusic M, Vlaski L (2013) Phage-antibiotic synergism: a possible approach to combatting Pseudomonas aeruginosa. Res Microbiol 164:55–60CrossRefPubMed
15.
Kaur S, Harjai K, Chhibber S (2012) Methicillin-resistant Staphylococcus aureus phage plaque size enhancement using sublethal concentrations of antibiotics. Appl Environ Microbiol 78:8227–8233CrossRefPubMedPubMedCentral
16.
Ventola CL (2015) The antibiotic resistance crisis: part 2: management strategies and new agents. Pharm Ther 40:344–352
17.
Viertel TM, Ritter K, Horz HP (2014) Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens. J Antimicrob Chemother 69:2326–2336CrossRefPubMed
18.
Chaudhry WN, Concepcion-Acevedo J, Park T, Andleeb S, Bull JJ, Levin BR (2017) Synergy and order effects of antibiotics and phages in killing Pseudomonas aeruginosa biofilms. PLoS One 12:e0168615CrossRefPubMedPubMedCentral
19.
Torres-Barcelo C, Hochberg ME (2016) Evolutionary Rationale for Phages as Complements of Antibiotics. Trends Microbiol 24:249–256CrossRefPubMed
20.
Yamaguchi K, Miyata R, Shigehisa R, Uchiyama J, Takemura-Uchiyama I, Kato S, Ujihara T, Sakaguchi Y, Daibata M, Matsuzaki S (2014) Genome analysis of Pseudomonas aeruginosa bacteriophage KPP23, belonging to the family Siphoviridae. Genome Announc 2:233–234CrossRef
21.
Uchiyama J, Suzuki M, Nishifuji K, Kato S, Miyata R, Nasukawa T, Yamaguchi K, Takemura-Uchiyama I, Ujihara T, Shimakura H, Murakami H, Okamoto N, Sakaguchi Y, Shibayama K, Sakaguchi M, Matsuzaki S (2016) Analyses of short-term antagonistic evolution of Pseudomonas aeruginosa strain PAO1 and phage KPP22 (Myoviridae family, PB1-like virus genus). Appl Environ Microbiol 82:4482–4491CrossRefPubMedPubMedCentral
22.
Shigehisa R, Uchiyama J, Kato S, Takemura-Uchiyama I, Yamaguchi K, Miyata R, Ujihara T, Sakaguchi Y, Okamoto N, Shimakura H, Daibata M, Sakaguchi M, Matsuzaki S (2016) Characterization of Pseudomonas aeruginosa phage KPP21 belonging to family Podoviridae genus N4-like viruses isolated in Japan. Microbiol Immunol 60:64–67CrossRefPubMed
23.
Miyata R, Yamaguchi K, Uchiyama J, Shigehisa R, Takemura-Uchiyama I, Kato S, Ujihara T, Sakaguchi Y, Daibata M, Matsuzaki S (2014) Characterization of a novel Pseudomonas aeruginosa bacteriophage, KPP25, of the family Podoviridae. Virus Res 189:43–46CrossRefPubMed
24.
Uchiyama J, Rashel M, Takemura I, Kato S, Ujihara T, Muraoka A, Matsuzaki S, Daibata M (2012) Genetic characterization of Pseudomonas aeruginosa bacteriophage KPP10. Arch Virol 157:733–738CrossRefPubMed
25.
Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458CrossRefPubMed
26.
Merabishvili M, Pirnay JP, Verbeken G, Chanishvili N, Tediashvili M, Lashkhi N, Glonti T, Krylov V, Mast J, Van Parys L, Lavigne R, Volckaert G, Mattheus W, Verween G, De Corte P, Rose T, Jennes S, Zizi M, De Vos D, Vaneechoutte M (2009) Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One 4:e4944CrossRefPubMedPubMedCentral
27.
Giamarellou H (2002) Prescribing guidelines for severe Pseudomonas infections. J Antimicrob Chemother 49:229–233CrossRefPubMed
28.
29.
Stanley P (1976) Isolation and characterization of phages for Ancalomicrobium adetum. J Gen Virol 32:37–43CrossRef
30.
Torres-Barcelo C, Franzon B, Vasse M, Hochberg ME (2016) Long-term effects of single and combined introductions of antibiotics and bacteriophages on populations of Pseudomonas aeruginosa. Evol Appl 9:583–595CrossRefPubMedPubMedCentral
31.
Torres-Barcelo C, Arias-Sanchez FI, Vasse M, Ramsayer J, Kaltz O, Hochberg ME (2014) A window of opportunity to control the bacterial pathogen Pseudomonas aeruginosa combining antibiotics and phages. PLoS One 9:e106628CrossRefPubMedPubMedCentral
32.
Nouraldin AAM, Baddour MM, Harfoush RAH, Essa SAAM (2016) Bacteriophage-antibiotic synergism to control planktonic and biofilm producing clinical isolates of Pseudomonas aeruginosa. Bull Alexandria Fac 52:99–105
33.
Chan BK, Abedon ST, Loc-Carrillo C (2013) Phage cocktails and the future of phage therapy. Future Microbiol 8:769–783CrossRefPubMed
34.
Oechslin F, Piccardi P, Mancini S, Gabard J, Moreillon P, Entenza JM, Resch G, Que YA (2017) Synergistic interaction between phage therapy and antibiotics clears Pseudomonas aeruginosa infection in endocarditis and reduces virulence. J Infect Dis 215:703–712PubMed
Metadata
Title
Piperacillin and ceftazidime produce the strongest synergistic phage–antibiotic effect in Pseudomonas aeruginosa
Authors
Jumpei Uchiyama
Ryu Shigehisa
Tadahiro Nasukawa
Keijiro Mizukami
Iyo Takemura-Uchiyama
Takako Ujihara
Hironobu Murakami
Ichiro Imanishi
Koji Nishifuji
Masahiro Sakaguchi
Shigenobu Matsuzaki
Publication date
01-07-2018
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 7/2018
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-018-3811-0

Other articles of this Issue 7/2018

Archives of Virology 7/2018 Go to the issue

Original Article

Molecular investigation of foot-and-mouth disease virus circulating in Pakistan during 2014-17

Original Article

Laser-cut paper-based device for the detection of dengue non-structural NS1 protein and specific IgM in human samples

Brief Report

Association of Interleukin-17F gene polymorphisms with susceptibility to severe enterovirus 71 infection in Chinese children

Brief Report

A barnavirus sequence mined from a transcriptome of the Antarctic pearlwort Colobanthus quitensis

Original Article

Induction of a high-titered antibody response using HIV gag-EV71 VP1-based virus-like particles with the capacity to protect newborn mice challenged with a lethal dose of enterovirus 71

Original Article

Molecular and biological characterization of a novel mild strain of citrus tristeza virus in California
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits